Mumbai-based biotech startup TechInvention Lifecare based has claimed positive outcomes of its recombinant subunit SARS-CoV-2 vaccine (CoviTech) in a ‘single dose’ preliminary study.

Enthused with the promising preliminary results, the company is now advancing further development of the vaccine.

While CoviTech is being positioned as an affordable, effective and safe vaccine for the masses, the company is also exploring another vaccine candidate targeting the conserved and immunogenic regions of the virus. This vaccine may have the potential to address the burning issue of mutations,  especially the  ‘Variants of Concern’  (VOC) which has been hammering countries through subsequent waves of infection.  

“We are thankful to the leadership of  BSC BioNEST  Bio-Incubator at the  Regional Centre for Biotechnology, Faridabad, India for providing us with the required state-of-the-art research infrastructure for the development of our vaccine through incubation,” said Syed  S Ahmed, Founder, Director & CEO, TechInvention. He further added,  “We are in discussion with potential pharma companies interested in manufacturing affordable vaccines for developing countries”.